GRI Bio (GRI) vs Redhill Biopharma (RDHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Redhill Biopharma is the larger company by market cap ($5.1 million vs $3.7 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | RDHL |
|---|---|---|
| Share price | $1.68 | $0.578 |
| Market cap | $3.67M | $5.14M |
| 1-day change | -9.19% | +21.94% |
| Forward P/E | — | 19.27 |
| EPS (TTM) | $-14.71 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $64.12 | $2.14 |
| 52-week low | $1.36 | $0.435 |
| Distance from 52-week high | -97.38% | -72.99% |
| Analyst consensus | none | — |
| Avg. price target upside | +1001.19% | — |
| Average volume | 328.24K | 2.05M |
| Shares outstanding | 2.19M | 8.89M |
| Employees | 3 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Redhill Biopharma
RDHL stock →RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
GRI vs RDHL FAQ
Which is bigger, GRI Bio or Redhill Biopharma?
Redhill Biopharma (RDHL) is larger, with a market capitalization of $5.14M compared with $3.67M for GRI Bio (GRI).
Are GRI Bio and Redhill Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.